The survey by Beba et al. (2019) focused on evaluating the impact of berberine on C-reactive protein (CRP) levels and found a significant reduction of −0.64 mg/L (95% CI: −0.67 to −0.61) in patients with conditions such as acute coronary syndrome, hypertension, and type 2 diabetes. This evidence concerns the gene CRP and acute coronary syndrome.